Policy implications of rationalization of statin use in Lithuania

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 3, 2009, Pages 419-424

  Kadusevicius, Edmundas ^a   Jankauskiene, Danguole ^b   Paulauskaite, Inga ^a   Slapikas, Rimvydas ^a,c  

^a KAUNAS UNIVERSITY OF MEDICINE HOSPITAL   (Lithuania)

^b MYKOLAS ROMERIS UNIVERSITY   (Lithuania)

^c KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Cost minimization; Economics; Epidemiology; Reference price; Statins

Indexed keywords

ATORVASTATIN; COST MINIMIZATION; EDUCATION PROGRAMS; ESTIMATED COSTS; EUROPEAN UNION COUNTRIES; FINANCIAL RESOURCES; HEALTH-CARE SYSTEM; INDIRECT COSTS; LITHUANIA; POLICY IMPLICATIONS; STATINS;

COST BENEFIT ANALYSIS; ECONOMIC ANALYSIS; HEALTH CARE; OPTIMIZATION;

COSTS;

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CALCULATION; CLINICAL ASSESSMENT; COMPARATIVE STUDY; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG USE; ECONOMIC EVALUATION; EDUCATION PROGRAM; EUROPEAN UNION; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; LITHUANIA; METHODOLOGY; PUBLIC HEALTH SERVICE; REIMBURSEMENT; COST; DECISION MAKING; ECONOMICS; HUMAN; PUBLIC HEALTH;

COSTS AND COST ANALYSIS; DECISION MAKING; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LITHUANIA; NATIONAL HEALTH PROGRAMS;

EID: 70350464610     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990158     Document Type: Article

References (16)

1. Bonita R, Beaglehole R, Kjellström T. Basic epidemiology. 2nd ed. World Health Organization. http://whqlibdoc.who. int/publications/2006/ 9241547073-eng.pdf (accessed January 24, 2008).
2. Burne J. Statins: The truth. 2007. http://www.dailymail.co.uk/ health/article-432395/Statins-truth.html (accessed March 16, 2008).
3. Danish Medicines Agency. Statistics grouped according to constituents, 2002-2006. http://dkma.medstat.dk/ MedStatDataViewer.php (accessed March 16, 2008).
4. Danzon PM. Reference pricing: Theory and evidence. http://hc. wharton.upenn.edu/danzon/PDF%20files/barcelonaeditfinal% 20.pdf (accessed January 28, 2008).
5. Estonian Medical Statistics Bureau. Estonian Statistics on Medicines 2002-2006. http://www.ravimiamet.ee/11880 (accessed March 17, 2008).
6. Hirsch M, O'Donnell J, OlssonA. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol. 2005;104:251-256.
7. Jacobson TA. Clinical context: Current concepts of coronary heart disease management. Am J Med. 2001;110:3-11.
8. Lithuanian Health Information Centre. http://www.lsic.lt (accessed 24 February 24, 2008).
9. National Agency for Medicines, Finland. Drug consumptions statistics. http://www.nam.fi/instancedata/prime-product-julkaisu/laakelaitos/embeds/ laakekulutus-2006-Medicines-in-2006.pdf (accessed June 11, 2009)
10. Norwegian Prescription Database. Drug consumption in Norway. http://www.legemiddelforbruk.no/english/ (accessed 16 March 16, 2008).
11. Senes S, Penm E. Medicines for cardiovascular health: Are they used appropriately? Australian Institute of Health and Welfare: http://www.aihw.gov. au/publications/cvd/mfchatua/ mfchatua-c00.pdf (accessed March 16, 2008).
12. Silva M, Matthews ML, Jarvis C, et al. Meta analysis of druginduced adverse events associated with intensive dose statin therapy. Clin Ther. 2007;29:253-260.
13. Strom BL. Statins and over-the-counter availability. N Engl J Med. 2005;352:1403-1405.
14. The National AIDS Treatment Advocacy Project. UK government backs generic statins: Pravastatin, simvastatin. http://www.natap.org/2007/newsUpdates/ 010507-07.htm (accessed April 5, 2008).
15. Wilson AE. De-mystifying pharmacoeconomics. Drug Benefit Trends 2005;11:56-67.
16. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/ (accessed October 18, 2008).